Annexin receives approval to start Phase 2 study in U.S.

Annexin Pharmaceuticals has been given the go-ahead by FDA to start the planned phase 2 clinical trial with the drug candidate ANXV in patients with retinal vein occlusion (RVO). STOCKHOLM (5 April, 2022)...

Annexin signs exclusive licensing deal in cancer

Annexin Pharmaceuticals AB (publ) has entered into a license agreement with Stanford University, CA, USA granting Annexin Pharmaceuticals exclusive license to patent rights related to use of Annexin A5...

Approval of COVID19-study

 Maastricht University Hospital receives approvals to start study with Annexin Pharmaceuticals drug candidate, ANXV, in patients with COVID19.  STOCKHOLM, SWEDEN (January 19, 2022) – Annexin Pharmaceuticals AB ...
Back to top